Stay updated with breaking news from Ranjits Bindra. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Ranjit S. Bindra, MD, PhD, discusses a new class of DNA modifiers which selectively target tumor DNA with the goal of overcoming resistance mechanisms across multiple types of cancer.
A nanoparticle-based treatment developed by researchers at Yale and the University of Connecticut is aimed at fighting glioblastoma.
A nanoparticle-based treatment developed by researchers at Yale and the University of Connecticut is aimed at fighting glioblastoma.
E-Mail IMAGE: Identification of potential regulators of the selective alt-NHEJ inhibition of mibefradil. (A) A schematic representation of the Relative Assessment of DNA Repair (RADAR) plot showing the significance of the different... view more Credit: Correspondence to - Yulia V. Surovtseva - yulia.surovtseva@yale.edu and Ranjit S. Bindra - ranjit.bindra@yale.edu Creation of a new class of radiosensitizers for glioblastoma based on the mibefradil pharmacophore" which reported that this group previously identified a calcium channel blocker, mibefradil, as a potential GBM radiosens...